SEOUL -- A smartphone application for wearable insulin delivery, which was developed by EOFlow, a provider of wearable drug delivery solutions, has obtained medical device approval in South Korea. The app can monitor and control the insulin injection of a tubeless, wearable pump.
The Ministry of Food and Drug Safety has approved Narsha, which is known to be the world's first app that can control insulin injection from a wearable pump, EOFlow said in a statement. It integrates a separate continuous glucose monitoring sensor and allows users to monitor their blood glucose levels.
The company has developed its wearable and disposable insulin pump, EOPatch, that can be replaced at a set time and is light and cost-competitive by using low-power high-performance electric osmosis pump technology.
EOPatch consists of a wearable insulin pump, a smartphone-like controller called "ADM" and diabetes management software. The history of injection can be stored for up to 90 days. Data synced to the app or web for analysis can be shared with guardians or medical personnel.
EOFlow has developed Narsha because cybersecurity is essential for devices or apps connected to an insulin injector via Bluetooth. Hacking can leak personal information and cause malfunction. Narsha has met all the cybersecurity requirements, the company said, predicting high demand in the market.
"Narsha has more advanced screen design which brings improved usability," an unnamed EOFlow official was quoted as saying. EOPatch installed with a separate controller will be launched in South Korea on March 29. The Narsha app will be released in about two months after user manuals and educational materials are prepared.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.